QSS
ALNY icon

Quantitative Systematic Strategies’s Alnylam Pharmaceuticals ALNY Stock Holding History

Quantitative Systematic Strategies’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,480
Closed -$251K – 29
2021
Q2 		$251K Sell
1,480
-2,964
-67% -$434K 0.09% 374
2021
Q1 		$627K Buy
4,444
+2,888
+186% +$435K 0.1% 324
2020
Q4 		$202K Sell
1,556
-901
-37% -$120K 0.03% 562
2020
Q3 		$358K Buy
+2,457
New +$349K 0.06% 397
2019
Q3 		– Sell
-6,477
Closed -$470K – 462
2019
Q2 		$470K Buy
+6,477
New +$497K 0.09% 261
2018
Q3 		– Sell
-5,493
Closed -$541K – 614
2018
Q2 		$541K Buy
+5,493
New +$545K 0.1% 324
2016
Q1 		– Sell
-3,189
Closed -$301K – 415
2015
Q4 		$301K Buy
+3,189
New +$296K 0.08% 747
2015
Q2 		– Sell
-3,711
Closed -$400K – 503
2015
Q1 		$400K Buy
+3,711
New +$376K 0.11% 259

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Quantitative Systematic Strategies's ALNY Position: Q3 2021 in Review

Quantitative Systematic Strategies sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2021, closing a stake of 1,480 shares — an estimated $251K sold.

Quantitative Systematic Strategies first reported a position in ALNY in Q1 2015 and held it in 8 quarters. The position peaked at $627K in Q1 2021. 403 funds tracked by Wall St. Rank hold ALNY as of Q3 2021.

  • Quantitative Systematic Strategies reported no remaining Alnylam Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Quantitative Systematic Strategies sold 1,480 Alnylam Pharmaceuticals shares in Q3 2021, an estimated $251K.
  • Quantitative Systematic Strategies first reported a position in Alnylam Pharmaceuticals in Q1 2015 and held it in 8 quarters.
  • Quantitative Systematic Strategies's Alnylam Pharmaceuticals position peaked at $627K in Q1 2021.
  • 403 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2021.

Based on Quantitative Systematic Strategies's 13F filing for Q3 2021, filed 16 Nov 2021.